Fulcrum Therapeutics, Inc. Overview
Pro stress-test →Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small molecules to improve the lives of patients with genetically defined diseases in areas of high unmet medical need. The company's lead candidate is pociredir, an oral small molecule designed to treat sickle cell disease and beta-thalassemia through fetal hemoglobin induction.
Strategic Profile
Pro stress-test →Pociredir showed rapid, robust, clinically relevant response with mean fetal hemoglobin increasing 12.2% at Week 12, with 58% of patients achieving HbF levels ≥20% and 58% reporting zero vaso-occlusive crises. Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026, pending FDA feedback.
Competitive Landscape
Pro stress-test →Pociredir faces competition from several approved therapies and ongoing clinical trials for sickle cell disease, including gene therapies and small molecule treatments. The company's proprietary EED inhibitor approach targeting fetal hemoglobin induction offers a differentiated oral mechanism compared to complex gene therapy alternatives.
Industry Context
Fulcrum Therapeutics, Inc. operates in Biopharmaceuticals - Rare Diseases & Hematology.
Key facts
Headquarters: Cambridge, Massachusetts, US · Market cap: $773M